Bone marrow transplants in genetic diseases.
The first paper [9] advocating the displacement use of bone marrow transplantation (DBMT) to treat a variety of genetic metabolic diseases (including thalassaemia major) was put before a European Working Party in 1978. It evolved from mainly Westminster experience which showed the need [6] for DBMT and first successfully used donors other than matched siblings [9]. The principles of using DBMT to install a donor marrow as a component factory which can last a lifetime are outlined. It is not a panacea, being applicable to only about 7% of known inborn errors. Worthwhile correction of some 50 previously disabling diseases in over 700 patients has already been achieved worldwide and for most of the survivors no further treatment is used after 1 year. Guidelines for future extension, including gene transplants, are offered. The superior results of elective DBMT (about 95%) should encourage paediatricians to aim for earlier diagnoses and evaluations for transplants.
Hobbs
J R
JR
Westminster Children's Bone Marrow Team, Department of Immunology, Charing Cross and Westminster Medical School, London, United Kingdom.
D016026:Bone Marrow Transplantation / Q000276:immunology; D002648:Child; D015316:Genetic Therapy; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000276:immunology / Q000628:therapy*; D014019:Tissue Donors